-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Three projects of Guangxiang Pharmaceutical, a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, have been selected as major science and technology special projects and science and technology program projects of Cangzhou City.
Category:
发布时间：2025-01-15
【概要描述】
Recently, three technological advancement and industrialization projects of Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, were selected as major science and technology special projects and science and technology program projects by Cangzhou City, which will further accelerate the company’s technological upgrading and product innovation, and provide policy support for the ongoing drive to elevate products toward high-end, branded, and green development.
Recently, three technological advancement and industrialization projects of Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, were selected as major science and technology special projects and science and technology program projects by Cangzhou City, which will further accelerate the company’s technological upgrading and product innovation, and provide policy support for the ongoing drive to elevate products toward high-end, branded, and environmentally friendly development.
Among the selected projects, “R&D and Industrialization of the Active Pharmaceutical Ingredient Penthoxifylline” has been approved as a Major Science and Technology Special Project for Cangzhou City for the 2023–2024 period; “Mechanism of Accumulation and Control of Genotoxic Impurities in a Novel Synthesis Process for Butylphenol Based on the Full Life Cycle” has been approved as a Municipal Natural Science Fund Project; and “Optimization of the Chiral Synthesis Process of Procaterol Based on Artificial Intelligence and Its Application Expansion” has been approved as a Key Municipal Science and Technology Project under the “Challenge-Based Recruitment” initiative.
As a high-value-added active pharmaceutical ingredient, the raw material theophylline has long posed significant challenges to the industry due to low purity, high production costs, and substantial environmental compliance pressures in conventional manufacturing processes. Guided by these issues, Guangxiang Pharmaceutical has focused on breakthroughs in key technologies—including condensation reactions, intermediate purification, and environmentally friendly wastewater treatment—and has achieved notable results, securing two authorized invention patents and one utility model patent.
Butylphthalide is a synthetic compound indicated for the treatment of mild to moderate acute ischemic stroke. Based on research into the synthetic route of butylphthalide, Guangxiang Pharmaceutical has continuously conducted systematic analytical studies on potential genotoxic impurities that may be introduced during manufacturing, thereby establishing an impurity profile, elucidating their sources and accumulation mechanisms, and developing appropriate control strategies. These efforts provide a theoretical basis for the analysis of trace-level genotoxic impurities and for the establishment of relevant pharmaceutical standards, thereby ensuring the safety and efficacy of the drug.
Procaterol is a third-generation adrenergic agent, yet conventional production methods are cumbersome and costly. Leveraging an industry–university–research innovation platform, Guangxiang Pharmaceutical has partnered with renowned universities to conduct integrated research on AI and asymmetric synthesis, thereby optimizing the manufacturing process for chiral drugs, enhancing the production efficiency of procaterol and other chiral alcohol-based pharmaceuticals, reducing production costs, and ultimately strengthening the market competitiveness of its products.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091